Table of contents
In This Issue
p415 | doi:10.1038/nrd1115
Editorial: Miss Manners might not approve
p417 | doi:10.1038/nrd1128
Research Highlights
Viral infections: A double whammy for hep C
p419 | doi:10.1038/nrd1116
Anticancer drugs: Switch control
p420 | doi:10.1038/nrd1117
Gluten intolerance: Inhibitors for human TGM2 enzyme
p420 | doi:10.1038/nrd1118
Lead discovery: Piecing together phosphatase inhibitors
p421 | doi:10.1038/nrd1119
Obesity: Turning on fat burning
p422 | doi:10.1038/nrd1120
Malaria: Overcoming antifolate drug resistance
p422 | doi:10.1038/nrd1121
Neurodegenerative diseases: COX-2 on the brain
p423 | doi:10.1038/nrd1122
In brief
ADME | Anticancer Drugs | Cardiovascular Disease | Anticancer Drugs
p423 | doi:10.1038/nrd1123
Patent watch
A new twist on the chiral switch
p424 | doi:10.1038/nrd1124
Drug delivery: Container traffic
p424 | doi:10.1038/nrd1125
News and Analysis
From the analyst's couch
Vision impairment therapies
p425 | doi:10.1038/nrd1113
Fresh from the Pipeline
Aripiprazole
p427 | doi:10.1038/nrd1114
Reviews
Article series: A guide to drug discovery
A guide to drug discovery: Predicting therapeutic value in the lead optimization phase of drug discovery
Terry Kenakin
p429 | doi:10.1038/nrd1110
The impact of drug-induced QT interval prolongation on drug discovery and development
Bernard Fermini & Anthony A. Fossa
p439 | doi:10.1038/nrd1108
Ophthalmic drug discovery
Abbot F. Clark & Thomas Yorio
p448 | doi:10.1038/nrd1106
Neurotrophic factors as novel therapeutics for neuropathic pain
Dinah W.Y. Sah, Michael H. Ossipo & Frank Porreca
p460 | doi:10.1038/nrd1107
Therapeutic strategies for rheumatoid arthritis
Josef S. Smolen & Günter Steiner
p473 | doi:10.1038/nrd1109
Perspective
Timeline
The prospect for bacteriophage therapy in Western medicine
Carl R. Merril, Dean Scholl & Sankar L. Adhya
p489 | doi:10.1038/nrd1111
